Lab1636 — Harvard–Deerfield R&D Alliance

Lab1636 is Harvard Office of Technology Development’s strategic R&D alliance with Deerfield Management, and it exists to support the development of novel therapeutics. The alliance is backed by a $100 million commitment from Deerfield, making it one of the more substantial translational routes attached to Harvard’s innovation ecosystem and a clear example of university-industry collaboration around biomedical development. The program is open to Harvard researchers working on biomedical or therapeutic projects and operates on a rolling basis rather than a fixed annual deadline. The application path is staged: a letter of intent comes first, then confidential review, and then a full proposal for projects that move forward. The extracted record does not publish a public award matrix, so the public-facing description is better anchored in the alliance structure, the therapeutic focus, and the ongoing review model than in a size table. Lab1636 is best for teams that need a disciplined path into therapeutic development and can operate comfortably in a confidential, partner-backed review process. The program suits work that already has a plausible drug-development story and needs a capital partner with a long horizon. Proposals are strongest when they show why the science matters therapeutically, how the project can be advanced through the staged process, and why the Harvard–Deerfield structure is the right environment for the next step.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.